

GlycArt Biotechnology AG

From Inception to trade sale – and what happened after...

Dr. Joël Jean-Mairet

Brussels, March 31, 2011

From the Idea to Spin-off from the Swiss Federal Institute of Technology

1996	At the midst his PhD thesis Pablo Umaña generates hypothesis/idea (lab of late Professor James E.
	Bailey)
	Idea is the starting basis of PhD thesis of Joël Jean-Mairet under supervision of Pablo Umaña
	 Strong know-how in metabolic engineering, recombinant protein expression in mamalian cells
1998	 Positive first in vitro results with an anti-CE7 antibody for neuroblastoma
	 US provisional patent application submitted April 1998.
1999	 Publication in Nature Biotechnology February 1999
	 PCT patent application submitted
	 Further validation of technology with recombinant chimeric anti-CD20 Mab
2000	 Start Business plan competition (ETH and McKinsey & Co)
	 Assignment of coach within BP competition: Dr. Georges Haas (retired former global head of preclinical research at Ciba Geigy)
	 June ranked among the top 10 business plans nationwide
	 September founding of GLYCART Biotechnology
2001	 Start of operations of GLYCART Biotechnology (3 people) with CHF 3 mio start capital

ysios.

capital


partners

Company evolution – Snap shot



capital

Technology is optimally placed in the value chain



ysios.


capital partners



Integrated antibody development company from target to early clinical trials

- Focus on clinically validated targets
- Start with best possible and clearly differentiated molecule from day one
- Non-core tasks outsourced
- Technology validation by selective partnering & PoC
- Carefully limit the availability of the technology keeping all in process IP and key materials in-house

Early stage product pipeline (2005)



ysios.


capital partners

Value proposition for prospective VCs or potential acquirers

- Unique technology to enhance potency of MAbs
- Proprietary pipeline with two lead compounds
- Potential of reducing clinical trial attrition rate by starting with best possible MAbs
- Potential impact in life-cycle management
- Credible Management and Board with track record of creating value

VSIOS.


partners





Consideration	Objective
Price	 Obtain the highest possible share price
Fit / future stage	 Partner that understands the business and able to give the additional scale
Timing	 45 days to new offers, 90 days to completion
Confidentiality	 No leakage into public domain of intended transaction
Secure current offer	 Maintain the interest of current party and achieve highest price with lowest earn out
Stakeholders	 Take into account stakeholder objectives (e.g. All employees)

The full process was completed in less than three months



ysios.

capital partners




- As of January 1, 2010 GlycArt Biotechnology AG is named **Roche Glycart AG**
- Roche Glycart workforce has increased approx 3 fold
- GlycArt preclinical research pipeline has led to 3 clinical programs (2 in preparation for entering phase III clinical trials)
- Worst financial crisis since 1929
- Investment bank and some GlycArt venture investors do not exist anymore
- Steady MAb licensing/collaborative deal flow from 2000-2005 followed by large consolidations
- Market forecasts back in 2004 completely underestimated the market potential of Mabs (USD 33bn vs USD 16.7bn projected for 2008)





- Professor's Support (established network, economic support, laboratory space)
- Negotiations with University
- "What is missing?"
- Patent application: First contact with lawyers






- First step in network creation
- Wording, structure, source of specialized information
- Business plan gave solid view of the short term future
- Credibility
- Raised capital for starting operations






- Value creation should be a major driving force
- Use of foundations and government funds
- Talk to the fiscal authorities
- Look for cost-efficient buzz
- Hire the best people



VSIOS.



ysios.



"Caminante no hay camino,

se hace camino al andar"

Antonio Machado